Table 1.
Ten‐year cumulative US FAERS reports of fracture associated with PPIs
|
Drug‐event counts | Drug counts | Event counts | Total counts | PRR (95% CI) | PRR (95% CI) |
|---|---|---|---|---|---|---|
| 2015–07 | 2015–07 | 2015–07 | 2015–07 | 2005–01 | 2015–07 | |
| Prilosec a | 61 | 34,053 | 3,510 | 4,370,123 | 2.29 (0.57–9.27) | 2.25 (1.75–2.90) |
| Omeprazole b | 130 | 105,128 | 3,510 | 4,370,123 | 1.24 (0.39–3.90) | 1.56 (1.31–1.86) |
| Nexium a | 146 | 84,955 | 3,510 | 4,370,123 | 2.40 (0.76–7.56) | 2.20 (1.86–2.59) |
| Esomeprazole b | N/A | N/A | ||||
| Dexilant a | 5 | 2,774 | 3,510 | 4,370,123 | N/A | 2.25 (0.93–5.40) |
| Dexlansoprazole b | ||||||
| Prevacid a | 56 | 43,985 | 3,510 | 4,370,123 | 2.05 (0.76–5.57) | 1.59 (1.22–2.08) |
| Lansoprazole b | 56 | 44,130 | 3,510 | 4,370,123 | N/A | 1.54 (1.18–2.02) |
| Zegerid a | 2 | 824 | 3,510 | 4,370,123 | N/A | 3.15 (0.79–12.56) |
| Omeprazole & Sodium Bicarbonate b | N/A | N/A | ||||
| Protonix a | 42 | 34,809 | 3,510 | 4,370,123 | 0.65 (0.09–4.67) | 1.57 (1.16–2.13) |
| Pantoprazole b | 62 | 53,103 | 3,510 | 4,370,123 | N/A | 1.56 (1.21–2.01) |
| AcipHex a | 13 | 12,346 | 3,510 | 4,370,123 | 0.99 (0.14–7.07) | 1.31 (0.76–2.26) |
| Rabeprazole b | 15 | 13,198 | 3,510 | 4,370,123 | N/A | 1.42 (0.85–2.35) |
Brand name producta and its generic equivalent.b N/A = not on the market yet or just approved or no data are available.
PRR statistics provides a very basic analysis that only accounts for statistical associations in the coreporting of drugs and suspected ADRs. It is entirely based on aggregate numbers of reports and disregards the strength of individual reports.